{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:11:23Z","timestamp":1770678683473,"version":"3.49.0"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,3,15]]},"DOI":"10.2169\/internalmedicine.1726-18","type":"journal-article","created":{"date-parts":[[2018,11,18]],"date-time":"2018-11-18T22:33:23Z","timestamp":1542580403000},"page":"843-847","source":"Crossref","is-referenced-by-count":18,"title":["Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone"],"prefix":"10.2169","volume":"58","author":[{"given":"Shuku","family":"Sato","sequence":"first","affiliation":[{"name":"Division of Hematology, Shonan Kamakura General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Kambe","sequence":"additional","affiliation":[{"name":"Division of Hematology, Shonan Kamakura General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yotaro","family":"Tamai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Shonan Kamakura General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chayakulkeeree M, Perfect JR. Cryptococcosis. Infect Dis Clin North Am 20: 507-544, 2006.","DOI":"10.1016\/j.idc.2006.07.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lui G, Lee N, Ip M, et al. Cryptococcosis in apparently immunocompetent patients. QJM - Mon J Assoc Physicians 99: 143-151, 2006.","DOI":"10.1093\/qjmed\/hcl014"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Baddley JW, Perfect JR, Oster RA, et al. Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease. Eur J Clin Microbiol Infect Dis 27: 937-943, 2008.","DOI":"10.1007\/s10096-008-0529-z"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE. Cryptococcosis and idiopathic CD4 lymphocytopenia. Medicine (Baltimore) 86: 78-92, 2007.","DOI":"10.1097\/md.0b013e31803b52f5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375: 1319-1331, 2016.","DOI":"10.1056\/NEJMoa1607751"},{"key":"6","unstructured":"6. Kumar SK, Sybil Biermann J, Castillo JJ, et al. NCCN Guidelines Version 1.2019 Multiple Myeloma NCCN Guidelines Panel Disclosures Continue [Internet]. [cited 2018 Apr. 12]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol 171: 100-108, 2015.","DOI":"10.1111\/bjh.13532"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bowcock SJ, Yip K, Majumder K, Atta M, Ceesay MM. Cryptococcosis in late stage multiple myeloma: consider it. Br J Haematol 176: 687, 2017.","DOI":"10.1111\/bjh.14496"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Oshima K, Kanda Y, Nannya Y, et al. Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol 67: 1-5, 2001.","DOI":"10.1002\/ajh.1067"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kontoyiannis DP, Peitsch WK, Reddy BT, et al. Cryptococcosis in patients with cancer. Clin Infect Dis 32: E145-E150, 2001.","DOI":"10.1086\/320524"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 50: 291-322, 2010.","DOI":"10.1086\/649858"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sun HY, Alexander BD, Lortholary O, et al. Lipid formulations of amphotericin B significantly improve outcome in solid organ transplant recipients with central nervous system cryptococcosis. Clin Infect Dis 49: 1721-1728, 2009.","DOI":"10.1086\/647948"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. de Weers M, Tai Y-T, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186: 1840-1848, 2011.","DOI":"10.4049\/jimmunol.1003032"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 121: 482-488, 2004.","DOI":"10.1309\/74R4TB90BUWH27JX"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Santonocito AM, Consoli U, Bagnato S, et al. Flow cytometric detection of aneuploid CD38 (++) plasmacells and CD19 (+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk Res 28: 469-477, 2004.","DOI":"10.1016\/j.leukres.2003.09.015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Karakasheva TA, Waldron TJ, Eruslanov E, et al. CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer. Cancer Res 75: 4074-4085, 2015.","DOI":"10.1158\/0008-5472.CAN-14-3639"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Flores-Borja F, Bosma A, Ng D, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 5: 173ra23, 2013.","DOI":"10.1126\/scitranslmed.3005407"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Deaglio S, Vaisitti T, Billington R, et al. CD38\/CD19: a lipid raft-dependent signaling complex in human B cells. Blood 109: 5390-5398, 2007.","DOI":"10.1182\/blood-2006-12-061812"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128: 384-395, 2016.","DOI":"10.1182\/blood-2015-12-687749"},{"key":"20","unstructured":"20. Van de Donk NW, Adams H, Vanhoof G, et al. Daratumumab in combination with lenalidomide plus dexamethasone results in persistent natural killer (NK) cells with a distinct phenotype and expansion of effector memory T-cells in pollux, a phase 3 randomized study. Blood 130: 3124, 2017."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375: 754-766, 2016.","DOI":"10.1056\/NEJMoa1606038"},{"key":"22","unstructured":"22. Rainer B, Stefan Steidl JE. Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide. J Clin Oncol 33: 8588, 2015."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res 23: 4290-4300, 2017.","DOI":"10.1158\/1078-0432.CCR-16-3192"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/6\/58_1726-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T15:37:41Z","timestamp":1572968261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/6\/58_1726-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1726-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]}}}